Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

17.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.3K
Experimental RNAi02:15

Experimental RNAi

6.5K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.5K
RNA Interference01:23

RNA Interference

26.8K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

412
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
412

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early-onset neuroinflammation drives neurodegeneration caused by lysosomal PI(3,5)P<sub>2</sub> insufficiency.

Neurobiology of disease·2026
Same author

In vivo adenine base editing ameliorates Dravet syndrome phenotypes in a mouse model.

Science translational medicine·2026
Same author

Developmental dysregulation of chandelier cell excitability in a mouse model of Dravet Syndrome.

bioRxiv : the preprint server for biology·2026
Same author

A hit for base editing: treatment of developmental epilepsy in a mouse model.

The Journal of clinical investigation·2026
Same author

Base editing rescues seizures and sudden death in a SCN8A mutation-associated developmental epileptic encephalopathy model.

The Journal of clinical investigation·2026
Same author

Novel mouse model reveals neurodevelopmental origin of PMM2-CDG brain pathology.

bioRxiv : the preprint server for biology·2025
Same journal

Microbiota-Based Interventions Differentially Rescue Gut and Social Behavior Phenotypes in Drosophila with Kdm5 Deficiency.

Developmental neuroscience·2026
Same journal

Maternal Infection Induces Neuronal Structure and Behavioural Alterations in Experimental Meningitis Rat Model.

Developmental neuroscience·2026
Same journal

Development of the Gut Microbiota throughout the First Year of Life and Its Association with Socio-Emotional Development into Childhood.

Developmental neuroscience·2026
Same journal

Intranasal Inhibition of Tropomyosin Receptor Kinase B Signaling during Early Postnatal Development Disrupts Growth and Sensorimotor Maturation in Neonatal Rodents.

Developmental neuroscience·2026
Same journal

Long-Term Consequences of Preterm Birth: A Lifespan Perspective.

Developmental neuroscience·2026
Same journal

From Womb to Weaning: Microbial Signals That Shape the Developing Brain.

Developmental neuroscience·2026
See all related articles

Related Experiment Video

Updated: Oct 23, 2025

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System
07:47

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System

Published on: October 29, 2019

19.0K

Antisense Oligonucleotide Therapy for Neurodevelopmental Disorders.

Sophie F Hill1,2, Miriam H Meisler1,2

  • 1Neuroscience Graduate Program, University of Michigan, Ann Arbor, Michigan, USA.

Developmental Neuroscience
|August 19, 2021
PubMed
Summary
This summary is machine-generated.

Antisense oligonucleotides (ASOs) offer versatile therapeutic strategies for genetic neurological disorders. These short molecules demonstrate diverse mechanisms for correcting gene expression and splicing defects, highlighting their potential in treating conditions like spinal muscular atrophy and Batten

Keywords:
Antisense oligonucleotideDravet syndromeGene therapySCN8ASpinal muscular atrophy

More Related Videos

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

13.9K
Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

61.1K

Related Experiment Videos

Last Updated: Oct 23, 2025

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System
07:47

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System

Published on: October 29, 2019

19.0K
Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

13.9K
Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

61.1K

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Antisense oligonucleotides (ASOs) are emerging therapeutics targeting gene expression and mRNA splicing.
  • The FDA has approved ASOs for ten genetic disorders, with numerous applications under development.
  • ASOs show promise for treating a range of neurodevelopmental and neuromuscular disorders.

Purpose of the Study:

  • To elucidate the molecular mechanisms of ASO treatment in four distinct neurodevelopmental and neuromuscular disorders.
  • To showcase the diverse applications and therapeutic potential of ASOs in neurological conditions.

Main Methods:

  • Description of molecular mechanisms for ASO action.
  • Case examples including nusinersen for spinal muscular atrophy (SMA).
  • Patient-specific ASO (Milasen) for CLN7 Batten disease.
  • ASO (STK-001) targeting SCN1A gene expression.
  • ASO targeting SCN8A mRNA reduction in epilepsy models.

Main Results:

  • Nusinersen corrects SMN2 splicing defects in SMA.
  • Milasen rescues CNL7 splicing in Batten disease.
  • STK-001 enhances SCN1A expression via poison exon exclusion.
  • ASO targeting SCN8A mRNA demonstrates therapeutic effects in mouse models of epileptic encephalopathy.

Conclusions:

  • ASOs exhibit a variety of mechanisms for treating genetic neurological disorders.
  • These examples underscore the broad applicability of ASOs in neurodevelopmental and neuromuscular diseases.
  • ASO technology represents a significant advancement in the therapeutic landscape for rare genetic neurological conditions.